Treatment Strategies and Challenges in Chronic Lymphocytic Leukemia
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia
Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia
At 4 years, there was no significant difference in overall survival.
Acalabrutinib Seems Safe and Efficacious in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Umbralisib Shows Promise Among Patients With CLL Intolerant to BTK, PI3K Inhibitors
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
CLL/SLL: Ibrutinib, Venetoclax Therapy May Improve Outcomes in First Line
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
MEK Inhibitors May Overcome Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Certain Mutations May Be Associated With Infection Risk for Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Anti-CD20 Antibody Improved Response to Ibrutinib in High-Risk R/R CLL
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...